Head-to-head evidence
albuterol HFA (Armstrong's) vs Albuterol Sulfate (Provenetil-HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Armstrong's)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled study with an adequate sample size measuring lung function directly, but no results have been posted yet, so the outcome is unknown.
Albuterol Sulfate (Provenetil-HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
Proventil-HFA serves here as the active reference product against which the investigational albuterol-HFA is compared in a secondary analysis, while the trial's main comparison is between the investigational product and placebo; no results have been posted yet.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Armstrong's)'s landscape · Albuterol Sulfate (Provenetil-HFA)'s landscape